Anixa Biosciences Partners with VERDI Solutions to Advance Real-World Evidence-Based Cancer Vaccines

Anixa Biosciences Partners with VERDI Solutions to Advance Real-World Evidence-Based Cancer Vaccines

Anixa Biosciences, Inc., a biotechnology company focused on cancer treatment and prevention, has announced a letter of intent with Vienna-based VERDI Solutions GmbH to develop personalized and off-the-shelf peptide vaccines for cancer patients. VERDI utilizes artificial intelligence and cloud computing to accelerate the design of individualized cancer vaccines, tailoring them to each patient’s tumor profile. Their approach has already been appli…